Conventional Medicine Skeptical Position

Why this article exists

If you go searching the internet for “are peptides safe?” you’ll find two camps shouting past each other.

One camp — generally peptide-positive sites, including ours — emphasizes mechanism, decades of animal evidence, real-world clinical practice across functional medicine, and the supply-chain risk-mitigation lever (verified vendor + Certificate of Analysis) that closes the most-cited safety concern. We weight animal data as first-class evidence because for many of these compounds, animal trials are the entire evidence base — see Peptides for pets — what the science says about peptide therapy for dogs and cats for the cross-species framing.

The other camp — mainstream-medicine evidence-based-medicine physicians — emphasizes the absence of completed published human randomized controlled trials, the failure history of compounds the peptide community currently promotes (zombie drugs abandoned by pharma after failed trials), the documented purity problems in the research-chemical supply chain, and the informed-consent gap that comes from prescribing compounds whose safety and efficacy profiles aren’t characterized.

Most of the public peptide content you read collapses one side or the other. Pure peptide marketing pretends mainstream skepticism doesn’t exist or is industry-funded propaganda. Pure mainstream skepticism pretends the practitioner-camp clinical experience and the animal evidence aren’t real. Neither side is fully right, and OHM thinks the user deserves to see both. That’s how informed adults make decisions.

The mainstream-medicine case in its strongest form

The clearest articulation of the conventional-medicine skeptical position in long-form podcast format is the Docs Who Lift × Barbell Medicine crossover discussion (Nadolsky, Nadolsky, Baracki, Feigenbaum, 2025). Four MDs, openly transparent that they could brand their own peptide line for millions if they wanted to and choose not to. That disclosure matters — it preempts the “they’re just protecting pharma profits” dismissal that gets aimed at most peptide-skeptical physicians. These speakers are not industry-funded mouthpieces. They are evidence-standard advocates, and the steel-manned version of their argument is what this article engages.

Their core argument: have a standard and articulate it

The central claim is structural, not anti-peptide. They argue that anyone recommending or using a therapeutic compound should be able to articulate, out loud, what evidence standard they’re applying. Their preferred standard is “some form of randomized trial controlled with placebo in humans” — not necessarily FDA approval, but some structured human-evidence threshold.

Their challenge to the peptide camp is direct: what’s your standard? If the honest answer is “I’ve seen people feel better when they use it,” that’s a standard, but it’s a standard that has historically failed across many compounds where careful trials later revealed harm or no benefit. They cite the CAST trial (antiarrhythmic drugs increased mortality despite suppressing arrhythmias — biology suggested they’d help, RCTs showed they killed more patients), the CETP inhibitor torcetrapib (raised HDL, killed more patients via off-target aldosterone effect), fen-phen, and the historical case where conventional medicine considered beta-blockers contraindicated in heart failure until trials proved they were beneficial.

Their point: biological plausibility alone is a notoriously unreliable predictor of clinical outcomes. Without RCTs, you can’t tell which intuitions are right and which are wrong. The 90s antiarrhythmic camp was confident they were saving lives. They weren’t.

Their position on FDA approval

They explicitly do not defend the FDA as infallible. Their position is more careful: you’d want some minimum data set on how a drug works, what it interacts with, what to monitor — not necessarily “ironclad stuff just to get it approved.” They cite the Elixir Sulfanilamide tragedy (1930s, sulfa drug + radiator-fluid solvent killed ~100 patients) as the historical lesson that drove the modern FDA structure, and the HIV/AIDS-era expanded-access programs as the lesson that ironclad regulation can also cost lives in different ways.

What they’re advocating for is not “trust the FDA blindly.” It’s “have a structured evidence standard, even if it’s lower than full FDA approval, and articulate it openly.” That’s a defensible position even from an evidence-asymmetry-aware lens.

Their specific empirical claim about supply chains — the JAMA SARMs study

This is the most important empirical anchor in their argument, and OHM substantially agrees with it.

Van Wagoner et al. 2017, JAMA (PMID 29183075): researchers purchased 44 products marketed and sold online as Selective Androgen Receptor Modulators (SARMs), then analyzed them by mass spectrometry using the same protocols used in anti-doping operations. The findings:

• 9% (4 of 44) contained no active compound detected
• 25% (11 of 44) contained substances not listed on the label
• Only 41% (18 of 44) had the labeled amount of active compound
• 52% (23 of 44) contained any actual SARM
• 39% (17 of 44) contained other unapproved drugs — including ibutamoren (MK-677), GW501516, and SR9009

Their argument extends from this: if research-chemical SARMs sold through the “not for human consumption” loophole have this purity profile, the assumption that research-chemical peptides are reliably what they say they are is unsupported. Same supply lanes. Same regulatory absence.

OHM’s editorial position: the JAMA SARMs study is one of the strongest published anchors for the supply-chain-is-the-real-risk thesis that runs through the entire OHM peptide editorial voice. We agree with the mainstream-medicine speakers entirely on this empirical point. Where we diverge is the conclusion. They conclude “therefore don’t use peptides.” We conclude “therefore only use peptides from vendors with documented third-party COAs, US manufacturing, and verified ≥99% purity — and skip the gray market entirely.” Same data. Different prescription.

Their position on specific peptides

The speakers do not have a blanket anti-peptide position. They explicitly endorse FDA-approved peptide therapeutics where the evidence base is strong:

• Semaglutide, Tirzepatide, and the broader GLP-1 receptor agonist class — “mountains of evidence.”
• Retatrutide — cautiously endorsed; “more evidence is emerging.”
• Tesamorelin — endorsed for the FDA-approved indication (HIV-associated lipodystrophy); skeptical of off-label use in healthy adults given the IGF-1 mitogen concern (which OHM also surfaces).
• PT-141 / Bremelanotide / Vyleesi — endorsed for the FDA-approved indication (HSDD in women).

Their skepticism focuses on:

• BPC-157 — they note that ~90% of all BPC-157 research comes from the same research group (Sikiric et al.) and that no published peer-reviewed human randomized trial of BPC-157 exists. They cite the Pliva development history: the Croatian pharmaceutical company that originally developed BPC-157 ran Phase I and Phase II ulcerative-colitis enema trials in the 2000s, never published the results, and abandoned the compound. OHM’s position: the no-published-RCT gap is real and we’ve stated it openly in the BPC-157 wiki — including the verification record that retired the fabricated viral “Nature P53 80% metastasis” cancer claims. We also weight the substantial animal evidence base and the decades of clinical-practice observations differently than the speakers do. Both can be true simultaneously: the human-trial gap is real AND the animal/mechanism/clinical-practice evidence is real.
• TB-500 — they argue there’s some topical-wound-healing data but nothing on injected systemic use. OHM’s position differs on the equine and companion-animal evidence base (covered in Peptides for pets — what the science says about peptide therapy for dogs and cats) and the systematic preclinical record.
• CJC-1295 — they cite a trial shutdown after a patient had a heart attack. The primary-source pin on this isn’t published in a major database, but the trial-shutdown event is widely reported in the peptide literature. Worth knowing about.
• MK-677 (Ibutamoren) / Ibutamoren — they note a documented congestive-heart-failure signal in trials. MK-677 is now being studied in pediatric growth-hormone-deficiency populations under FDA supervision. OHM’s position: the CHF safety tail is real and is reflected in the MK-677 wiki’s safety section.
• Melanotan II — they specifically call out rhabdomyolysis and acute kidney injury cases reported in users. OHM agrees — melanotan has the highest-risk safety profile of any commonly-discussed peptide and the OHM wiki carries a red safety flag accordingly.
• AOD-9604 — they cite completed Phase II obesity trials with negative efficacy results, after which the developer abandoned the compound. OHM agrees — AOD-9604 has the cleanest “evidence says it doesn’t work” record of any compound in the metabolic-fat-loss cluster. See Metabolic / fat-loss peptides cluster — AOD-9604, HGH Fragment 176-191, Adipotide, AICAR, SLU-PP-332.
• MOTS-c — they note no human trials have been done. OHM’s position: the human-trial gap is real and is acknowledged in the MOTS-c wiki; the animal evidence base is more substantial than the speakers characterize, but they’re not wrong about the human-evidence gap.

Their argument about the “if it worked, big pharma would sell it” framing

This is the argument OHM most directly disagrees with — and it’s important to surface it fairly.

Their version: if a compound were genuinely safe and effective, pharma economics would have brought it to market. The fact that BPC-157, CJC-1295, MK-677, AOD-9604, and other research peptides have either failed pharma trials or been abandoned by their developers is evidence that the compounds don’t work as advertised. They counter the patent argument by noting that even when an endogenous peptide fragment isn’t patentable in its base form, the synthetic manufacturing process IS patentable, AND the FDA offers exclusivity protections to the first company to bring a compound to market.

OHM’s editorial disagreement: pharma economics doesn’t reward small markets, compounds that compete with patented drugs in the same indication, or trials where the cost vastly exceeds the addressable market. Insulin’s history is the textbook counter — Banting and Best famously gave the original insulin patent away for $1. The peptide cluster has a similar dynamic: many of the compounds are old, unpatentable in their endogenous form, and the trial economics for a fat-loss or healing indication don’t pencil for a compound that would compete with patented GLP-1 receptor agonists or biologics in the same indication. Pharma abandonment of a compound is one data point, not a verdict on the compound’s biological merit. Abandonment can equally indicate “the molecule didn’t work” OR “the economics didn’t work,” and the conventional-medicine speakers don’t always distinguish those cases.

That said: the speakers’ point is not zero-content. The Pliva BPC-157 history IS a yellow flag. The AOD-9604 failure IS a red flag. OHM’s position is “weigh the abandonment alongside the mechanism and the clinical-practice base, don’t dismiss it.” That’s a different position than “dismiss the compound because it was abandoned,” and it’s a different position than “ignore the abandonment because pharma is corrupt.” Both extremes are unserious.

Where OHM and mainstream medicine converge

It’s worth listing the points of agreement plainly, because these are where the strongest customer-protective advice lives.

• Supply chain matters more than the molecule. Both camps agree that the research-chemical gray market has serious quality-control problems documented by the JAMA SARMs study. OHM’s verified-vendor framework (Alyve, AminoClub, BioLongevity with third-party COAs) is OHM’s answer to this; the mainstream-medicine response is “avoid the gray market entirely.” Both answers address the same real problem.
• FDA-approved peptides used for FDA-approved indications are appropriate. GLP-1 receptor agonists, tesamorelin for HIV lipodystrophy, PT-141 / Vyleesi for HSDD. Both camps agree.
• Anecdote is not RCT. OHM tier-labels as a lower-confidence tier than or. The mainstream-medicine speakers make the same point in their language. The disagreement is on what weight to assign to evidence, not whether it deserves a distinct tier.
• Placebo effects in injectable compounds are real. Both camps acknowledge this. OHM applies the same caveat where relevant — the wiki’s “How to evaluate whether a peptide is working for you” framing flags subjective improvement as a signal that has to compete with placebo expectation.
• Some commonly-promoted peptides really aren’t benign. Melanotan II’s rhabdomyolysis/AKI signal, MK-677’s CHF tail, the documented melanotan-related skin-lesion concerns — both camps agree these are real safety signals that anyone considering these compounds needs to know about.
• The honest-disclosure principle. OHM discloses the affiliate commission rail openly on every relevant page. The mainstream-medicine speakers in the source video disclose that they could brand their own peptide line for millions if they wanted to. Transparency about incentives is the floor for trustworthy content on either side.

Where OHM and mainstream medicine actually disagree

Strip away the social-media noise and the real disagreement is narrower than either side’s loudest voices suggest:

1. Weight of animal evidence. OHM treats animal evidence as first-class for compounds where animal trials are the entire evidence base (which is most of the research peptides). Mainstream medicine treats animal evidence as preclinical-only — necessary but not sufficient for clinical recommendation.
2. Weight of practitioner-camp clinical observation. OHM treats decades of consistent practitioner observation across functional-medicine practices as-tier-but-meaningful signal. Mainstream medicine treats it as anecdote not different in kind from the hiccup-cure stories at the dinner table.
3. Interpretation of pharma abandonment. OHM weighs the patent + market-economics explanations alongside the “compound failed” explanation. Mainstream medicine treats abandonment as strong evidence of compound failure.
4. The informed-adult DIY pathway. OHM treats verified-vendor + Certificate-of-Analysis + an honest evidence-tiered information layer as a defensible self-directed path. Mainstream medicine treats unsupervised use as outside the bounds of responsible practice.

These are not stupid disagreements on either side. They’re disagreements about evidence weighting and acceptable risk under uncertainty. Reasonable people land in different places on them. The OHM editorial position is to surface both sides honestly, weight the evidence transparently, and let the user — armed with the full picture — decide where they personally land.

What this means for how you should think about it

If you’re trying to decide whether to use a research peptide right now, the honest synthesis is something like this:

• For FDA-approved peptides used for FDA-approved indications — semaglutide for weight loss, tirzepatide for weight loss, tesamorelin for HIV lipodystrophy, Vyleesi for HSDD — the evidence is solid, both camps agree, and the supply chain isn’t a major concern because you’re getting them from regulated pharmacy channels.
• For FDA-approved peptides used off-label — tesamorelin for body recomposition in a healthy adult, for example — you’re in the gray zone. The molecule is well-characterized, but the studied population is not your population, and the long-term data in your use case doesn’t exist. Work with a knowledgeable clinician, monitor what’s monitorable (IGF-1, age-appropriate cancer screening), and understand that you’re running an n=1 outside the trial frame.
• For research-chemical peptides — BPC-157, TB-500, MOTS-c, KPV, GHK-Cu, the GH-axis secretagogues — you’re in genuinely uncertain territory. The animal evidence is real. The mechanism is well-characterized for most of them. The clinical-practice base is substantial. The human-trial gap is also real. The supply chain matters enormously. The OHM-honest answer: if you decide to use these, use them from verified vendors with documented third-party COAs (Alyve / AminoClub / BioLongevity), at sensible doses, with attention to safety signals, and ideally with a clinician who actually knows the compound rather than a default “I don’t know, don’t take it” response. The mainstream-medicine answer: wait until the human evidence exists.
• For specific high-risk peptides — Melanotan II especially — both camps converge on caution. The risks are real, documented, and not worth the upside for most users.

The thing that makes OHM useful is that we put the actual question in front of you. “What is your evidence standard?” is the right question whether you’re approaching this from the practitioner-camp side or the mainstream-medicine side. Articulate yours. Make a decision you can defend out loud. That’s the whole framework.

Sources for the key factual claims

• Source video: Docs Who Lift × Barbell Medicine crossover, “The Truth About Peptides: Clinical Evidence vs. Social Media Hype” (2025). Spencer Nadolsky MD (host) + Karl Nadolsky MD + Austin Baracki MD + Jordan Feigenbaum MD. https://www.youtube.com/watch?v=2EUOkQPcM_0
• JAMA SARMs purity study: Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.” JAMA. 2017;318(20):2004–2010. PMID 29183075.
• BPC-157 unpublished trials: Pliva (Croatia) Phase I and Phase II ulcerative-colitis enema trials in the 2000s, never published. As of 2026 there is no published peer-reviewed human RCT of BPC-157 in any indication.
• CAST trial (antiarrhythmic suppression increased mortality): Echt et al. NEJM 1991;324:781–788. Standard cardiology canon.
• Torcetrapib safety signal: Barter et al. ILLUMINATE trial, NEJM 2007;357:2109–2122. Standard lipidology canon.
• Elixir Sulfanilamide 1937 tragedy: the historical event that drove modern FDA pre-market safety review structure.
• Beta blockers in heart failure (reversal of biological-plausibility assumption): CIBIS-II, MERIT-HF, COPERNICUS trials. Standard cardiology canon.
• Cardiovascular outcome trial requirements for diabetes drugs: FDA 2008 guidance prompted by Steve Nissen / Cleveland Clinic rosiglitazone safety analysis.

---

Last updated: 2026-06-20. Created per Rick’s editorial mandate to present both sides honestly. This article is OHM’s own synthesis of the strongest version of the mainstream-medicine skeptical position — not a verbatim transcript of the source video. All practitioner content paraphrased into OHM voice per Doctrine #3. Engages directly with the umbrella doctrine §2 “state the position, show the counter” requirement.